Jupiter Neurosciences, Inc. JUNS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 24.00% | 136.95% | 324.34% | 318.31% | -- |
| Gross Profit | -19.74% | -132.25% | -319.91% | -318.31% | -- |
| SG&A Expenses | 88.71% | 130.19% | 164.39% | 227.95% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.62% | 131.64% | 189.98% | 250.43% | -- |
| Operating Income | -70.50% | -130.64% | -189.27% | -250.43% | -- |
| Income Before Tax | -55.91% | -175.25% | -254.36% | -466.30% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.91% | -175.25% | -254.36% | -466.30% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.91% | -175.25% | -254.36% | -466.30% | -- |
| EBIT | -70.50% | -130.64% | -189.27% | -250.43% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -36.47% | -155.64% | -211.57% | -380.15% | -- |
| Normalized Basic EPS | -50.27% | -100.79% | -126.80% | -170.13% | -- |
| EPS Diluted | -36.65% | -152.56% | -206.71% | -333.47% | -- |
| Normalized Diluted EPS | -50.27% | -104.33% | -131.55% | -177.80% | -- |
| Average Basic Shares Outstanding | 15.75% | 14.04% | 18.62% | 18.30% | -- |
| Average Diluted Shares Outstanding | 15.75% | 11.28% | 15.59% | 15.14% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |